The results of a clinical trial of 'Hanmi Tams 0.4mg', a benign prostatic hyperplasia (BPH) medication launched by South Korean drugmaker Hanmi Pharm, were presented at the AUA (American Urological Association) AUA Annual Meeting, the largest gathering of urologists in the world.
Hanmi Pharm said on May 9 that Lee Seung-wook, professor of urology at Hanyang University, made a presentation on the results of a clinical trial of 'Hanmi Tams 0.4mg at the AUA Annual Meeting, held on May 7 in the US.
In the clinical trial, 494 men with BPH took Hanmi Tams 0.4mg, Tamsurosin 0.2mg or a placebo once a day for 12 weeks.
When the International Prostate Symptom Score (IPSS) was used in the evaluation of the severity of symptoms, Hanmi Tams 0.4mg was 71 percent more effective than 0.2mg in treating the disease. And there was no significant difference in adverse drug reaction (ADR) rates between Tamsurosin 0.2mg and Hanmi Tams 0.4mg.
Tamsurosin 0.4mg has been available in about 70 countries and the maximum dose is set at 0.8mg.o
However, Tamsurosin 0.2mg has been the only type available in S. Korea. Besides, doctors f find it hard to prescribe 0.2mg tablets for a single dose, because 0.2mg tablets for a single dose are uncovered by insurance.
'Hanmi Tams 0.4mg is the first Tamsulosin 0.4mg BPH medication that hit the Korean market in March.
